Supplementary Data

Supplementary Table S1. *Antibodies to AAV and hCNGB3 after subretinal injection of AAV5-PR2.1-hCNGB3 and AAV5-PR2.1-cCNGB3 in CNGB3-mutant dogs*

Animal ID	*Vector dose (vg/eye)*	*Antibodies to AAV*		*Antibodies to hCNGB3*	
		Pretreatment	*Week 12*	*Pretreatment*	*Week 12*
M728	5×10^{11}	40	160	Negative	Negative
M729	5×10^{11}	20	40	Negative	Negative
M730	5×10^{11}	20	160	Negative	Negative
M731	5×10^{10}	20	40	Negative	Negative
M732	5×10^{10}	20	40	Negative	Negative
M733	5×10^{10}	20	80	Negative	Negative

Each animal had a subretinal injection of AAV5-PR2.1-*hCNGB3* in one eye and AAV5-PR2.1-*cCNGB3* in the other eye. For AAV, results are expressed as the reciprocal of the highest serum dilution that inhibited expression of the β-galactosidase transgene by ≥50%. Antibodies to hCNGB3 were measured by ELISA. Canine CNGB3 protein was not available to use in antibody testing.